Leopoldo Baiza-Duran
Overview
Explore the profile of Leopoldo Baiza-Duran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
59
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Quinonez-Alvarado M, Chavez-Hurtado P, Caro-Palomera J, Nino-Trejo O, Jimenez-Dolores J, Munoz-Villegas P, et al.
Biologicals
. 2023 Sep;
84:101711.
PMID: 37748325
PRO-169 is an anti-VEGF monoclonal antibody developed by Laboratorios Sophia that shares its sequence with Bevacizumab (BVZ); though, PRO-169 is intended for intravitreal administration. In this study, analytical characterization showed...
2.
Sanchez-Rios A, Correa-Gallegos E, Medina-Espinoza J, Navarro-Sanchez A, Olvera-Montano O, Baiza-Duran L, et al.
Animal Model Exp Med
. 2022 Mar;
5(3):266-273.
PMID: 35277950
Background: The objective of this study was to validate an animal model for dry eye during and after the administration of 1% ophthalmic atropine sulfate (OAS) in New Zealand white...
3.
Munoz-Villegas P, Sanchez-Rios A, Quinonez-Alvarado M, Olvera-Montano O, Quintana-Hau J, Baiza-Duran L
J Exp Pharmacol
. 2021 Jun;
13:545-554.
PMID: 34113182
Background: PRO-169 is a biosimilar candidate to bevacizumab (BEV), a monoclonal antibody (mAb) that inhibits vascular endothelial growth factor-A (VEGF-A) developed for intravitreal use. The current study demonstrates the intraocular...
4.
Belalcazar-Rey S, Sanchez Huerta V, Ochoa-Tabares J, Altamirano Vallejo S, Soto-Gomez A, Suarez-Velasco R, et al.
Curr Eye Res
. 2020 Dec;
46(7):919-929.
PMID: 33289602
: To evaluate the efficacy of a preservative free sodium hyaluronate/chondroitin sulfate ophthalmic solution (SH/CS-PF) in patients with dry eye disease (DED).: This was a randomized phase IV, multicentric, prospective,...
5.
Baiza-Duran L, Sanchez-Rios A, Gonzalez-Baron J, Olvera-Montano O, Correa-Gallegos E, Navarro-Sanchez A, et al.
Int J Retina Vitreous
. 2020 Aug;
6:32.
PMID: 32742719
Background: To evaluate the retinal toxicity after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white (NZW) rabbit eyes. Methods: NZW rabbits were...
6.
Palacio-Pastrana C, Chavez-Mondragon E, Soto-Gomez A, Suarez-Velasco R, Montes-Salcedo M, Fernandez de Ortega L, et al.
Clin Ophthalmol
. 2020 Jul;
14:1581-1589.
PMID: 32606573
Background: The purpose of this study was to compare the efficacy and safety of difluprednate 0.05% (PRO-145) versus prednisolone acetate 1% (Prednefrin SF), for management of postoperative inflammation and pain,...
7.
Olvera-Montano O, Baiza-Duran L, Quintana-Hau J, Quinonez-Alvarado M, Zeng W, Gong L, et al.
Drug Des Devel Ther
. 2019 Dec;
13:3813-3821.
PMID: 31806932
Purpose: To evaluate the efficacy of a therapy on improving characteristics of laser-induced choroidal neovascularization (CNV) via single intravitreal injection of a humanized anti-human VEGF monoclonal antibody (PRO-169) versus bevacizumab...
8.
Chavez-Mondragon E, Palacio C, Soto-Gomez A, Villanueva-Najera M, De Wit-Carter G, Suarez-Velasco R, et al.
Clin Ophthalmol
. 2019 May;
13:781-787.
PMID: 31118556
This study evaluated the clinical efficacy and safety of bromfenac 0.09%, sodium hyaluronate 0.4% (SH) combination therapy, versus placebo and SH in a clinical model of pterygium I-III. A total...
9.
Gomez-Aguayo F, Paczka J, Lenero-Cordova R, Jimenez-Roman J, Davila-Villarreal J, Hartleben C, et al.
Ophthalmol Ther
. 2018 Apr;
7(1):145-156.
PMID: 29680880
Introduction: The aim of this prospective crossover study was to evaluate the non-inferiority of PRO-122 (a preservative-free fixed combination) compared with 0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide fixed...
10.
Baiza-Duran L, Olvera-Montano O, Mercado-Sesma A, Oregon-Miranda A, Lizarraga-Corona A, Ochoa-Tabares J, et al.
J Ocul Pharmacol Ther
. 2018 Apr;
34(3):250-255.
PMID: 29624493
Purpose: The purpose of this study was to evaluate the clinical efficacy and safety of a novel ophthalmic solution of pazufloxacin on the ocular surface of patients with bacterial conjunctivitis...